Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $16.04 million. The enterprise value is -$1.81 million.
Important Dates
The last earnings date was Tuesday, August 5, 2025, before market open.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 5.42 million shares outstanding. The number of shares has increased by 0.60% in one year.
| Current Share Class | 5.42M |
| Shares Outstanding | 5.42M |
| Shares Change (YoY) | +0.60% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 2.91% |
| Owned by Institutions (%) | 9.64% |
| Float | 5.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.72 |
| Forward PS | 27.03 |
| PB Ratio | 0.92 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.71, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.71 |
| Quick Ratio | 12.46 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -23.51% and return on invested capital (ROIC) is -17.96%.
| Return on Equity (ROE) | -23.51% |
| Return on Assets (ROA) | -16.76% |
| Return on Invested Capital (ROIC) | -17.96% |
| Return on Capital Employed (ROCE) | -32.57% |
| Revenue Per Employee | $263,007 |
| Profits Per Employee | -$281,702 |
| Employee Count | 16 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $200 in taxes.
| Income Tax | 200 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.48% in the last 52 weeks. The beta is 1.24, so Lipocine's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -40.48% |
| 50-Day Moving Average | 3.20 |
| 200-Day Moving Average | 3.89 |
| Relative Strength Index (RSI) | 36.10 |
| Average Volume (20 Days) | 36,327 |
Short Selling Information
The latest short interest is 100,395, so 1.85% of the outstanding shares have been sold short.
| Short Interest | 100,395 |
| Short Previous Month | 112,601 |
| Short % of Shares Out | 1.85% |
| Short % of Float | 1.91% |
| Short Ratio (days to cover) | 3.23 |
Income Statement
In the last 12 months, Lipocine had revenue of $4.21 million and -$4.51 million in losses. Loss per share was -$0.84.
| Revenue | 4.21M |
| Gross Profit | 4.21M |
| Operating Income | -5.58M |
| Pretax Income | -8.49M |
| Net Income | -4.51M |
| EBITDA | -5.52M |
| EBIT | -5.58M |
| Loss Per Share | -$0.84 |
Full Income StatementBalance Sheet
The company has $17.94 million in cash and $251,519 in debt, giving a net cash position of $17.68 million or $3.26 per share.
| Cash & Cash Equivalents | 17.94M |
| Total Debt | 251,519 |
| Net Cash | 17.68M |
| Net Cash Per Share | $3.26 |
| Equity (Book Value) | 17.13M |
| Book Value Per Share | 3.19 |
| Working Capital | 16.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.99 million and capital expenditures -$90,086, giving a free cash flow of -$5.08 million.
| Operating Cash Flow | -4.99M |
| Capital Expenditures | -90,086 |
| Free Cash Flow | -5.08M |
| FCF Per Share | -$0.94 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -132.59% and -107.11%.
| Gross Margin | 100.00% |
| Operating Margin | -132.59% |
| Pretax Margin | -107.10% |
| Profit Margin | -107.11% |
| EBITDA Margin | -131.26% |
| EBIT Margin | -132.59% |
| FCF Margin | n/a |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.60% |
| Shareholder Yield | -0.60% |
| Earnings Yield | -28.39% |
| FCF Yield | -31.97% |
Analyst Forecast
The average price target for Lipocine is $9.00, which is 204.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 204.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 36.22% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
Lipocine has an Altman Z-Score of -5.46 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.46 |
| Piotroski F-Score | 2 |
